Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 20, Issue 6, Pages 289-294

The Matrix Metalloproteinase-3 (MMP-3) 5A/6A Promoter Polymorphism Is Not Associated with Ischaemic Heart Disease: Analysis Employing a Family Based Approach

Paul G. McGlinchey,1 Mark S. Spence,1 Chris C. Patterson,2 Adrian R. Allen,3 Gillian Murphy,1 Damian Fogarty,3 Alun Evans,2 and Pascal P. McKeown1,3

1Regional Medical Cardiology Centre, Royal Victoria Hospital, Grosvenor Road, Belfast, BT12 6BA, UK
2Department of Epidemiology and Public Health, Queen's University Belfast, Mulhouse Building, Grosvenor Road, Belfast, Northern Ireland BT12 6BJ, UK
3Department of Medicine, Queen's University Belfast, Institute of Clinical Science, Grosvenor Road, Belfast, Northern Ireland BT12 6BJ, UK

Received 18 January 2005; Accepted 18 January 2005

Copyright © 2004 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Matrix metalloproteinase-3 (MMP-3) has been proposed as an important mediator of the atherosclerotic process. The possible role of the functional -1612 5A/6A polymorphism of the MMP-3 gene in the susceptibility to ischaemic heart disease (IHD) was investigated in a well-defined Irish population using two recently described family based tests of association. One thousand and twelve individuals from 386 families with at least one member prematurely affected with IHD were genotyped. Using the combined transmission disequilibrium test (TDT)/sib-TDT and the pedigree disequilibrium test (PDT), no association between the MMP-3 -1612 5A/6A polymorphism and IHD was found. Our data demonstrate that, in an Irish population, the MMP-3 -1612 5A/6A polymorphism is not associated with IHD.